标题
Precision Oncology: Evolving Clinical Trials across Tumor Types
作者
关键词
-
出版物
Cancers
Volume 15, Issue 7, Pages 1967
出版商
MDPI AG
发表日期
2023-03-27
DOI
10.3390/cancers15071967
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
- (2023) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
- (2022) Louisa R. Hoes et al. CLINICAL CANCER RESEARCH
- Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2022) Jean L. Grem et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2022) Gina M. Vaccaro et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
- (2022) Senthil Damodaran et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
- (2022) A. S. Mansfield et al. npj Precision Oncology
- Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.
- (2022) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- (2022) Gordan Srkalovic et al. JOURNAL OF CLINICAL ONCOLOGY
- 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study
- (2022) E. Ahn et al. ANNALS OF ONCOLOGY
- 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
- (2022) A.K. Ganti et al. ANNALS OF ONCOLOGY
- Clinical trial design in the era of precision medicine
- (2022) Elena Fountzilas et al. Genome Medicine
- Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
- (2022) Henry Hiep Vo et al. npj Precision Oncology
- Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
- (2022) Richard F. Little et al. BLOOD
- The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies
- (2021) Yonina R. Murciano-Goroff et al. CANCER CELL
- Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
- (2021) James M. Cleary et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2021) Ajjai S. Alva et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2021) Hussein Moustapha Ali-Ahmad et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
- (2021) John M. Wrangle et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2021) Evan P. Pisick et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2021) Scott Schuetze et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
- (2021) Hua Sun et al. Nature Communications
- A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
- (2021) Sylvia Adams et al. CLINICAL CANCER RESEARCH
- A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Non-Pancreatic Neuroendocrine Tumors
- (2020) Sandip P. Patel et al. CLINICAL CANCER RESEARCH
- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
- (2020) Douglas B. Johnson et al. CLINICAL CANCER RESEARCH
- Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.
- (2020) Ranju Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- (2020) Eyal Meiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.
- (2020) Kelsey Klute et al. JOURNAL OF CLINICAL ONCOLOGY
- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- Circulating tumor DNA analysis in the era of precision oncology
- (2020) Rabih Said et al. Oncotarget
- Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2020) Eugene R Ahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
- (2020) Evan P. Pisick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
- (2020) Young K. Chae et al. JOURNAL OF CLINICAL ONCOLOGY
- Review of precision cancer medicine: Evolution of the treatment paradigm
- (2020) Apostolia M. Tsimberidou et al. CANCER TREATMENT REVIEWS
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
- (2020) April K. S. Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2020) Tareq Al Baghdadi et al. Targeted Oncology
- Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2020) Julie G. Fisher et al. Targeted Oncology
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor
- (2020) Kevin Kalinsky et al. JAMA Oncology
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
- (2019) Jordi Rodon et al. NATURE MEDICINE
- Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
- (2019) K L Jhaveri et al. ANNALS OF ONCOLOGY
- Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
- (2019) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
- (2019) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- A simplified guide to randomized controlled trials
- (2018) Amar Bhide et al. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.
- (2018) Young Kwang Chae et al. JOURNAL OF CLINICAL ONCOLOGY
- Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.
- (2018) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
- (2017) Chih-Jian Lih et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
- (2016) M. Schwaederle et al. MOLECULAR CANCER THERAPEUTICS
- Precision medicine: lessons learned from the SHIVA trial
- (2015) Apostolia M Tsimberidou et al. LANCET ONCOLOGY
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now